The role of SEC14L4 in esophageal squamous cell cancer: insights into clinical relevance and molecular pathways.

IF 1.5 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2024-10-31 Epub Date: 2024-10-29 DOI:10.21037/tcr-24-1657

An Wang, Youbo Wang, Yanhui Chen, Posum Wan, Anwaar Saeed, Qinyun Ma, Xiaofeng Chen

{"title":"The role of SEC14L4 in esophageal squamous cell cancer: insights into clinical relevance and molecular pathways.","authors":"An Wang, Youbo Wang, Yanhui Chen, Posum Wan, Anwaar Saeed, Qinyun Ma, Xiaofeng Chen","doi":"10.21037/tcr-24-1657","DOIUrl":null,"url":null,"abstract":"Background: Esophageal squamous cell cancer (ESCC) is the most common type of esophageal cancer. This study aimed to elucidate the role of Saccharomyces cerevisiae-like 4 (SEC14L4) in ESCC.Methods: To elucidate the role of SEC14L4 in ESCC, this study analyzed the clinical data, gene sequencing data, and other relevant data retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) of the National Center for Biotechnology Information. The methodology involved several analytical approaches, including nomogram model analysis, co-expression analysis, gene set enrichment and variation analysis, weighted correlation network analysis, drug susceptibility analysis, and single-cell analysis. These methods were employed to evaluate the significance of SEC14L4 in ESCC. The expression of SEC14L4 was evaluated via quantitative real-time polymerase chain reaction (qRT-PCR).Results: SEC14L4 expression (P<0.001) was significantly elevated in those with ESCC, especially in patients with locally advanced disease (P=0.005), and indicated a poor prognosis (P=0.045). Findings from the nomogram model analysis identified the contribution of clinical indicators to survival prediction with good efficacy. Subsequently, the single-nucleotide polymorphisms and co-expressed genes of SEC14L4 were identified. Furthermore, pathways associated with SEC14L4, including DNA metabolic process, transcription factor binding, apoptosis, and others, were examined. Notably, SEC14L4 expression was predominantly observed in monocytes. Drug sensitivity analysis indicated the association of SEC14L4 expression with sensitivity of ESCC to the common chemotherapy drugs AICAR, BMS.708163, GNF.2, Nutlin.3a, PD.0325901, and RDEA119. Verification of the high expression of SEC14L4 in KYSE520 and KYSE150 was conducted, thereby confirming the study's findings.Conclusions: High expression of SEC14L4 is associated with poorer clinical outcomes, highlighting its potential as a therapeutic target and suggesting its involvement in the molecular mechanisms underlying ESCC.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5535-5549"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543032/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1657","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Esophageal squamous cell cancer (ESCC) is the most common type of esophageal cancer. This study aimed to elucidate the role of Saccharomyces cerevisiae-like 4 (SEC14L4) in ESCC.

Methods: To elucidate the role of SEC14L4 in ESCC, this study analyzed the clinical data, gene sequencing data, and other relevant data retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) of the National Center for Biotechnology Information. The methodology involved several analytical approaches, including nomogram model analysis, co-expression analysis, gene set enrichment and variation analysis, weighted correlation network analysis, drug susceptibility analysis, and single-cell analysis. These methods were employed to evaluate the significance of SEC14L4 in ESCC. The expression of SEC14L4 was evaluated via quantitative real-time polymerase chain reaction (qRT-PCR).

Results: SEC14L4 expression (P<0.001) was significantly elevated in those with ESCC, especially in patients with locally advanced disease (P=0.005), and indicated a poor prognosis (P=0.045). Findings from the nomogram model analysis identified the contribution of clinical indicators to survival prediction with good efficacy. Subsequently, the single-nucleotide polymorphisms and co-expressed genes of SEC14L4 were identified. Furthermore, pathways associated with SEC14L4, including DNA metabolic process, transcription factor binding, apoptosis, and others, were examined. Notably, SEC14L4 expression was predominantly observed in monocytes. Drug sensitivity analysis indicated the association of SEC14L4 expression with sensitivity of ESCC to the common chemotherapy drugs AICAR, BMS.708163, GNF.2, Nutlin.3a, PD.0325901, and RDEA119. Verification of the high expression of SEC14L4 in KYSE520 and KYSE150 was conducted, thereby confirming the study's findings.

Conclusions: High expression of SEC14L4 is associated with poorer clinical outcomes, highlighting its potential as a therapeutic target and suggesting its involvement in the molecular mechanisms underlying ESCC.

查看原文本刊更多论文

SEC14L4 在食管鳞状细胞癌中的作用：对临床相关性和分子通路的见解。

背景：食管鳞状细胞癌（ESCC）是最常见的食管癌类型。本研究旨在阐明类酿酒酵母4（SEC14L4）在ESCC中的作用：为了阐明 SEC14L4 在 ESCC 中的作用，本研究分析了从美国国家生物技术信息中心癌症基因组图谱（TCGA）和基因表达总库（GEO）中检索到的临床数据、基因测序数据及其他相关数据。该方法涉及多种分析方法，包括提名图模型分析、共表达分析、基因组富集和变异分析、加权相关网络分析、药物易感性分析和单细胞分析。采用这些方法评估了SEC14L4在ESCC中的重要性。通过实时定量聚合酶链反应（qRT-PCR）评估了SEC14L4的表达：结果：发现了SEC14L4的表达（PSEC14L4）。此外，还研究了与SEC14L4相关的通路，包括DNA代谢过程、转录因子结合、细胞凋亡等。值得注意的是，SEC14L4 主要在单核细胞中表达。药物敏感性分析表明，SEC14L4的表达与ESCC对常见化疗药物AICAR、BMS.708163、GNF.2、Nutlin.3a、PD.0325901和RDEA119的敏感性有关。对KYSE520和KYSE150中SEC14L4的高表达进行了验证，从而证实了研究结果：结论：SEC14L4的高表达与较差的临床预后相关，突出了其作为治疗靶点的潜力，并表明其参与了ESCC的分子机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.